54 results about "Immune status" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

The invention provides a hospital infection propagation path tracing method based on multi-source data fusion, and belongs to the technical field of infection propagation paths in hospitals, and the method comprises the steps: building a data set through collecting hospital multi-source infection monitoring data, constructing a multi-layer network propagation model comprising physical contact, spatial proximity and time co-occurrence, and carrying out the tracing of the multi-source infection propagation path. Community detection is carried out by using a random block model, infection propagation path identification is converted into graph coloring problem solving, an individual behavior heterogeneity model is established, and SEIR model propagation parameters are corrected by fusing individual characteristic parameters such as the immune state of a patient and the protection level of medical staff; a propagation situation awareness model based on a hybrid expert mechanism is adopted to optimize propagation parameter estimation, and a propagation parameter weight coefficient is obtained through a game optimization mechanism and Nash equilibrium solution for iterative optimization. And finally, outputting a high-confidence infection propagation path sequence and a propagation source positioning result by adopting a propagation path backtracking algorithm in combination with spatial-temporal correlation analysis.

Systems and methods to assess immune receptor sequences can incorporate a language model to yield embedded representations and classification of immune status. Classification systems and method can include assessment of embedded immune receptor sequence representations that account for isotype or V(D)J gene segment selection. Systems and methods to assess immunity status can incorporate one or more classifiers to predict immune status.

The invention relates to the field of medical diagnosis, and particularly discloses a biomarker combination and a kit for HIV / Mtb co-infection immune state evaluation and clinical diagnosis and application of the biomarker combination and the kit. Multi-factor detection is carried out on peripheral blood samples of an HIV infected person, an Mtb infected person and an HIV / Mtb co-infected person, Lasso regression screening is adopted to obtain cell factors closely related to HIV / Mtb co-infection, such as FGF-2, IL-7, I-309, TNF-alpha, MMP-1 and MMP-7, and a multi-factor diagnosis model is constructed. The model shows high sensitivity, specificity and AUC value in a training set and a test set, can effectively distinguish HIV individual infection and HIV / Mtb co-infection individuals, and is especially suitable for diagnosis of patients with low CD4 + T cell level. The marker combination provided by the invention and the kit prepared from the marker combination can be used as a supplement of an immunological detection method, and a new technical means is provided for clinical diagnosis and immune state evaluation of HIV / Mtb co-infection.

The invention belongs to the technical field of biomolecular markers, and particularly relates to a cross-animal general skeleton-derived hematopoietic stem cell marker gene set and a screening method thereof. According to the invention, a bone-derived hematopoietic stem cell marker gene set universal across animal categories is constructed for the first time, and the bone-derived hematopoietic stem cell marker gene set comprises at least five of Cdc42, Cbx, Tfam, Denr, Mcts1, Ak2, Ruvbl, Ahcy, Nna and Vdac; the hematopoietic stem cell marker gene set is obtained through cross-species homologous gene screening, the defect that a traditional vertebrate marker has no orthohomology in invertebrates is overcome, accurate recognition of HSC in shells is achieved, the hematopoietic stem cell marker gene set has species universality and cell specificity, the immune state of aquatic animals can be evaluated, disease-resistant breeding can be guided, and the application prospect is wide. And molecular evidence is provided for analyzing an evolution path of a hematopoietic system from invertebrates to vertebrates.

The present application relates to the field of medical immunology technology, and more particularly to biomarkers and their application in the assessment of liver damage in end-stage liver disease. In the present application, the proportion of CCR7+CD8+ T cells in CD8+ T cells is used as a marker for the assessment of liver damage in end-stage liver disease, which can reflect the liver immune status of end-stage liver disease, especially the assessment of the degree of liver damage, has high specificity and sensitivity, and provides a scientific basis for the development of clinical individualized treatment plan, and has good practical application value. At the same time, while reflecting the liver damage process of the patient, it can also reflect the immune status of the patient's liver, and can provide certain theoretical basis for slowing down the disease progression of subsequent biliary atresia and other end-stage liver disease patients with liver damage.

The present invention relates to a composition for diagnosing immunodeficiency or a method for providing information for diagnosis thereof. By using the composition and the method according to one aspect, it is possible to simply and effectively diagnose immune-deficient conditions such as immunosuppression or immune paralysis.

The invention discloses a hematologic tumor diagnosis and treatment primer group, a kit and application. The primer group comprises a first primer group and / or a second primer group, the first primer group is used for amplifying IGH, IGDH, IGK and IGL; the first primer group is used for amplifying TRB V-J, TRB D-J, TRG and TRD, the second primer group is used for amplifying TRB V-J, TRB D-J, TRG and TRD, after the primer groups amplify and rearrange sequences, the positive detection of clinical samples can be remarkably improved, the obtained CDR3 sequence can be used for clinical monitoring and can independently evaluate an immune group library of each patient, the immune state of an individual can be accurately reflected, the change condition of tumor cells of the patient can be dynamically monitored, and the clinical detection efficiency can be improved. And the method has good reliability and repeatability.

The invention provides a lung cancer microenvironment ecological characteristic detection and curative effect evaluation system, and relates to the technical field of lung cancer prognosis evaluation, and the system comprises a reading module which is used for reading slice information of a subject; the boundary construction module is used for constructing a region boundary according to the tumor region in the slice information; identifying tumor infiltrating lymphocytes (TILs for short) from the slice information, and determining the distribution type of the tumor infiltrating lymphocytes in combination with the distribution characteristics and the region boundary of the tumor infiltrating lymphocytes; the method comprises the following steps of: obtaining slice information, identifying a three-level lymphatic structure (TLS for short) from the slice information, and determining a distribution type of the three-level lymphatic structure in combination with distribution characteristics and a region boundary of the three-level lymphatic structure; and the evaluation module is used for performing prognosis effect prediction on the subject based on the distribution type of tumor infiltration lymphocytes and the distribution type of the three-level lymphatic structure, deeply analyzing the immune condition of a tumor micro-environment (TME for short), and improving the accuracy of prognosis evaluation.

Disclosed are methods and agents for predicting response to therapy, immune status and / or disease progression. More particularly, disclosed are methods, agents and kits for analyzing cellular distribution of PD-L2, including its nuclear localization, for stratifying a patient as a likely responder or non-responder to a therapy, for managing treatment of a patient with a therapy, for monitoring a disease in a patient following treatment with a therapy, for determining the status of a disease and / or for determining the immune status of a patient.

The invention discloses a hepatocellular carcinoma prognosis and treatment adaptability evaluation model based on mRNA vaccine antigen and a construction method. The method comprises the following steps: firstly, analyzing gene expression difference between normal tissues and hepatocellular carcinoma tumors, understanding mutation and genome structure change of hepatocellular carcinoma patients, and then further selecting genes related to the infiltration level of antigen presenting cells from abnormally expressed genes and mutant genes, and the genes having a significant relationship with the overall lifetime and disease-free lifetime of the patient, so as to obtain candidate mRNA vaccine neoantigen targets. Based on the expression level of the target, immunotyping is performed on the patient, and the patient population suitable for the mRNA vaccine is evaluated. Meanwhile, the relationship between the expression level of the target spot and the prognosis of the patient is quantified, so that the probability value that the total survival time of the hepatocellular carcinoma patient reaches 3 years and 5 years is predicted. According to the invention, the hepatocellular carcinoma treatment resistance and tumor immune state can be objectively and accurately evaluated, and the prediction accuracy of hepatocellular carcinoma treatment prognosis is improved.

The present invention relates to a biomarker HLA-DOA for sepsis-related diseases and a use thereof. The present invention provides a use of HLA-DOA or an active fragment or functional fragment thereof in the preparation of a product for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of sepsis-related diseases in a subject.

This invention discloses a prognostic and therapeutic suitability assessment model for hepatocellular carcinoma (HCC) based on mRNA vaccine antigens, and its construction method. First, the differences in gene expression between normal tissues and HCC tumors are analyzed to understand the mutations and genomic structural changes in HCC patients. Then, genes related to the level of antigen-presenting cell infiltration, as well as genes significantly related to overall survival and disease-free survival, are further selected from anomalously expressed and mutated genes to obtain candidate mRNA vaccine neoantigen targets. Based on the expression levels of these targets, patients are immunophenotyped to assess the patient population suitable for mRNA vaccines. Simultaneously, the relationship between target expression levels and patient prognosis is quantified to predict the probability of HCC patients achieving 3-year and 5-year overall survival. This invention can objectively and accurately assess treatment resistance and tumor immune status in HCC, improving the predictive accuracy of HCC treatment prognosis.

The invention discloses a 15-antibody combination for accurately detecting a mouse tissue immune cell subset and application of the 15-antibody combination. Aiming at the problems of large fluctuation and instability of detection results caused by adjustment of voltage and fluorescence compensation during detection by a flow cytometer and different processing modes during result analysis, the antibody combination disclosed by the invention takes monoclonal antibodies CD45, CD3, CD4, CD8, CD19, B220, Ly-6C, Ly-6G, MHC-II, CD11c, CD49b, CD62L, CD44 +, PD-1 and PD-L1 as effective components, and a stable and standard detection method for mouse tissue immune cell subsets is established. The method can analyze the proportion, number and distribution of various immune cells (T cells, B cells, NK cells, dendritic cells, mononuclear cells and granulocytes) in spleen, lung, liver, brain or kidney tissues of mice, can reflect the immune state of the mice and evaluate the immunosuppression state, and can be applied to the fields of disease models, drug evaluation, vaccine development and the like.

The present invention relates to a sepsis-related disease biomarker HLA-DQA and the use thereof. Provided in the present invention is the use of HLA-DQA or an active fragment and functional fragment thereof in the preparation of a product for early diagnosis, risk assessment, immune status assessment, prognosis prediction, and / or treatment regimen selection of a sepsis-related disease in a subject.

The invention provides a pathogen immune lineage evaluation method based on high-throughput antibody epitope spectrum detection data. The pathogen immune lineage evaluation method comprises the following steps: data preparation: obtaining sequencing data of an antigen epitope library and sample sequencing data after co-immunoprecipitation of a biological sample and library incubation; data preprocessing: performing quality control on all sequencing data; comparing and counting data: constructing a reference library index, comparing the indexes, and counting read segments of the disease epitope peptide segments; identifying epitope peptide fragments which are remarkably enriched in the sample; calculating a calibration coefficient; and calculating the enrichment immunocharacterization characteristics of the pathogens and judging whether the pathogens are positive immunoreactions or not. According to the EPIC scoring evaluation method, thousands of virus site information can be efficiently processed and summarized, the immune state of an individual for various pathogens is accurately evaluated, key information is extracted from high-throughput detection data, the binding condition of an antibody and an antigen epitope is accurately recognized, and a detection result is visually presented in an image visualization mode.

The invention belongs to the technical field of postoperative immune state evaluation of a patient suffering from thymoma, and particularly relates to a postoperative immune state monitoring and prognosis evaluation method for the patient suffering from thymoma. According to the method, the immune states of the patient are dynamically tracked by accurately monitoring and evaluating the immune states of the patient in different postoperative periods, the recovery condition of the postoperative immune function of the patient can be reflected by collecting blood samples of the patient in different postoperative periods and detecting the proportion of T cell subsets in the blood samples, and meanwhile, the recovery condition of the postoperative immune function of the patient can be accurately evaluated. According to the method, sample parameters are screened, classified and evaluated, invalid sample parameters are effectively removed, the accuracy of evaluating the immune state of the patient is improved, and therefore a more reliable evaluation basis is provided for doctors, the doctors are helped to formulate a more scientific and reasonable treatment scheme, and in addition, the treatment efficiency is improved. The prognosis risk level can be determined according to the immune deviation amount of the patient, and a more reliable prognosis evaluation basis is provided for doctors.

The present invention relates to a biomarker group of B cells and a use thereof. According to the present invention, a single-cell transcriptome analysis technology is used, and by analyzing single-cell gene expression profiles of B cells in cancerous and adjacent non-cancerous tissues of cancer patients, B cell subsets capable of reflecting a body's tumor immune status, namely, naïve B cells expressing genes Cd83 and Irs2, are isolated and characterized. Moreover, further studies identified that new characteristic genes Cd83 and Irs2 expressed by the cell subsets and the relationship between the proportion of naïve B cells and tumor prognosis can be used for diagnosis and monitoring of tumor prognosis, and as novel targets for tumor immunotherapy.

The present invention belongs to the technical field of traditional Chinese medicine preparations, and discloses a process for preparing an oral spray for inhibiting oral pathogens, comprising a tank body, a tank cover provided on the top of the tank body, a discharge pipe provided on the bottom of the tank cover, a control valve provided on the discharge pipe, a first motor fixedly mounted on the top of the tank cover, an output end of the first motor fixedly connected to a rotating shaft, one end of the rotating shaft extends through the tank cover to the interior of the tank body, and a first movable plate fixedly connected to the outer surface of the rotating shaft. Traditional Chinese medicine has a variety of active ingredients, such as flavonoids, volatile oils and polysaccharides, etc. These ingredients have broad-spectrum antibacterial, anti-inflammatory and therapeutic effects, providing a safer and more effective option for oral rehabilitation treatment. By comprehensively considering factors such as microbial composition, immune status and changes in oral mucosa, and by in-depth research on the regulatory effect of traditional Chinese medicine sprays on the oral microenvironment, a more comprehensive and accurate solution can be provided for post-implantation rehabilitation treatment, which is easy to use.

The present application provides methods of identifying the immune status of a subject, and use of a reagent for detecting IL-1R2 levels in a sample from a subject in the manufacture of a product for identifying the immune status of the subject. The present application also provides antibodies that bind human IL-1R2 and uses thereof, and hybridoma cells that produce antibodies that bind human IL-1R2 and uses thereof.

This invention relates to the field of traditional Chinese medicine composition technology, and particularly to an oral traditional Chinese medicine composition for treating multiple myeloma and its preparation method. It comprises the following components in parts by weight: Bupleurum chinense 10-12 parts, Cyperus rotundus 8-10 parts, Curcuma longa 8-10 parts, Oroxylum indicum 5-6 parts, Angelica sinensis 8-10 parts, Paeonia lactiflora 8-10 parts, Atractylodes macrocephala 10-12 parts, Poria cocos 10-12 parts, Codonopsis pilosula 8-10 parts, Glycyrrhiza uralensis (processed) 5-6 parts, Agrimonia pilosa 6-8 parts, Bambusa textilis 8-10 parts, Mentha haplocalyx 4-6 parts, and Zingiber officinale 4-6 parts. The composition provided by this invention not only directly inhibits the growth of myeloma cells, but also comprehensively improves the survival prognosis of model animals by regulating liver and spleen function, improving immune status, and reducing phlegm-heat and blood stasis. It provides a stable, safe, and easily promoted oral traditional Chinese medicine preparation for the clinical treatment of multiple myeloma.

This invention discloses a method and system for assessing immune age and status using transcriptomics. The invention provides the application of a gene composition highly correlated with age in assessing immune age and status. By utilizing the actual age of the user being tested and the expression levels of the aforementioned gene composition in their peripheral blood mononuclear cell transcriptome, immune age, immune rings, and immune aging index are analyzed to assess immune status. For users whose immune status deviates from the normal range, further classification of their immune status can be determined. This invention employs a machine learning-based approach to effectively extract immune age information from peripheral blood mononuclear cell transcriptome sequencing data, enabling a comprehensive assessment of immune status and providing effective guidance for health status.

The present invention relates to an immune sensitivity identification and regulation method based on the expression association of DUSP11 and nc886, and more specifically, to a method for providing immune response information, the method comprising a step for measuring the expression levels of DUSP11 and nc886. In the present invention, it was found that nc886 and DUSP11 are negatively correlated, and nc886 increases according to DUSP11 depletion in various cell types (epithelial cells, fibroblasts, and myofibroblasts). In addition, it was found that vtRNA in the 5'-PPP form increases upon depletion of DUSP11, thereby increasing immune response, but nc886 (vtRNA2-1) in the 5'-P form increases due to DUSP11 depletion, thereby decreasing immune response. That is, in the present invention, it was found that when the expression of nc886 in the 5'-P form increases as a result of DUSP11 depletion, inflammatory responses caused by IFN are alleviated due to the increased 5'-P-nc886, and thus the present invention can be used as a method for providing information on immune status using the correlation between nc886 and DUSP11.

The present invention belongs to the technical field of immune status assessment for thymoma patients, and specifically relates to a quantitative assessment system for the immune status of thymoma patients complicated with myasthenia gravis. By comprehensively analyzing the quantitative scores and abnormal confidence levels of the patients' immune indicators, the invention can more accurately assess the immune status of the patients. Compared with traditional assessment methods, the present invention not only considers the quantitative scores, but also introduces the parameter of abnormal confidence level, thereby improving the accuracy and reliability of the assessment results. In addition, by dynamically adjusting the assessment threshold, the assessment system can be made more flexible to adapt to the individual differences of different patients, further improving the accuracy and practicality of the assessment. At the same time, the present invention also constructs an immune status database to track and analyze the immune status data of patients for a long time, providing doctors with more comprehensive information on the immune status of patients.

Tumors use a variety of mechanisms to avoid the host's anti-tumor immune response. Humoral immune suppression is one of the mechanisms. Tumors produce circulating factors that can suppress antibody or complement-mediated immune responses to enhance their own survival. Mesothelin is a cell surface protein that is overexpressed by several cancer types that are associated with a microenvironment that exhibits immune suppression. Anti-mesothelin antibodies often suffer from such immune suppression microenvironments. However, an alternatively formatted anti-mesothelin antibody is effective in killing mesothelin-expressing cancers, independent of the tumor microenvironment immune status.

This invention discloses a set of biomarkers, scoring models, and applications for assessing immunotherapy response and / or prognosis in head and neck squamous cell carcinoma, relating to the field of biomedical technology. The biomarkers include ITGB1, FTH1, SPP1, CD3D, CXCL9, and IL2RB. The STRIDE score is obtained by calculating the geometric mean ratio of the expression levels of the aforementioned six biomarkers, which can be used to assess the likelihood of high or low response to immunotherapy and / or prognostic risk in subjects. This invention constructs a spatial domain scoring model based on the D4 and D5 / D6 spatial domains to obtain the STRIDE score, reflecting the patient's spatial immune status, thereby enabling the assessment of prognostic risk and the suitability of immunotherapy for patients with head and neck squamous cell carcinoma.

The invention provides a traditional Chinese medicine composition for regulating intestinal and liver skin axes and relieving aging and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following components in percentage by weight: 15-25% of pears, 10-15% of fish gelatin, 8-12% of wheat leaves, 8-12% of Chinese wolfberry fruits, 6-10% of rhizoma polygonati, 5-10% of radix salviae miltiorrhizae, 5-8% of poria cocos, 4-8% of Chinese yams and 2-5% of roses. According to the traditional Chinese medicine composition for regulating intestinal and liver skin axes and relieving senescence and the preparation method thereof provided by the invention, endotoxin accumulation is improved by regulating intestinal microecology; oxidation resistance (SOD and GSH levels are improved, and ROS is eliminated); the immune state of the skin is regulated, and inflammatory factors (TNF-alpha and IL-6) are reduced; collagen is supplemented, and skin repair and regeneration are promoted; the microcirculation is improved, and the nutrition supply and metabolic function of the skin are enhanced.

The present invention relates to a biomarker PAX5 for sepsis-related diseases and a use thereof. The present invention provides a use of PAX5 or an active fragment or functional fragment thereof in the preparation of a product for early diagnosis, risk assessment, immune status evaluation, prognostic prediction and / or treatment plan selection of a sepsis-related disease in a subject.

Systems and methods for predicting an immune response against a tumor in a patient having the tumor are provided. The relative mass or changes of mass of tumor cells or immune cell in the tumor can be ex vivo observed, and an immune status of the tumor can be determined based on the mass of tumor cells or immune cell. The immune status can provide a guidance to predict the immune response against the tumor in the patient.